

75. (new) The isolated nucleic acid molecule of claim 73, wherein the polypeptide comprises amino acids 22-221 of SEQ. ID NO:2.

76. (new) The isolated nucleic acid molecule of claim 73, wherein the polypeptide comprises amino acids 1-221 of SEQ ID NO:2.

✓ 77. (new) The isolated nucleic acid molecule of claim 73, wherein the polypeptide comprises amino acids 19-221 of SEQ ID NO:2.

78. (new) The isolated nucleic acid molecule of claim 73, wherein the polypeptide comprises amino acids 19-224 of SEQ ID NO:2.

79. (new) An isolated nucleic acid molecule comprising a polynucleotide encoding a polypeptide at least 80% identical to SEQ ID NO:2, or a fragment thereof, wherein the polypeptide binds CD48.

80. (new) An isolated nucleic acid molecule comprising a polynucleotide at least 80% identical to SEQ ID NO:1.

B1
J 81. (new) The isolated nucleic acid molecule of claim 73, wherein the polypeptide comprises SEQ ID NO:6.

✓ 82. (new) The isolated nucleic acid molecule of claim 73, wherein the polypeptide comprises SEQ ID NO:7.

83. (new) The isolated nucleic acid molecule of claim 73, wherein the polypeptide comprises SEQ ID NO:8.

84. (new) A recombinant vector comprising the nucleic acid molecule of any one of claims 73 through 83.

85. (new) A host cell transfected or transduced with the vector of claim 84.

86. (new) A method for the production of NK cell Activation Ligand (NAIL) polypeptide comprising culturing a host cell that has been genetically engineered to express the nucleic acid of claim 73 under conditions promoting expression of the polypeptide.

87. (new) The method of claim 86, further comprising recovering the polypeptide.

88. (new) The method of claim 87, wherein the host cell is a mammalian cell.

89. (new) The method of claim 88, wherein the host cell is a CV-1/EBNA cell.

REMARKS

To summarize, non-elected claims 37-47, 51-53, 58, and 60-72 have been cancelled without prejudice to future prosecution of the cancelled subject matter in a related application. Applicants request that Group III claims 48-50, 54-57, and 59 be cancelled without prejudice to future filing, and that new claims 73-89 set forth above be entered. Claims 73-89 are provided in the attached Appendix.

Basis for claims 73 to 89 are found in the specification. Basis for claim 73 is found on page 21, line 20 to 24, page 23, line 1 through 17, page 24, lines 13 to 21, and page 45, lines 7 to 13, for example, of the specification. Basis for claim 74 is found in the specification, page 24, lines 13 to 21. Basis for claim 75 is found in the specification on page 21, lines 21 to 23; basis for claim 76 is found on page 22, lines 6 and 7; basis for claims 77 and 78 are found on page 22, lines 22 to 24; basis for claim 79 is found on page 17, lines 20 to 23, and page 21, line 20 to page 22, line 24. Basis for claim 80 is found on page 17, lines 20 to 23. Basis for claim 81 is found on page 29, lines 14 to 28. Basis for claim 82 is found on page 25, line 29 to page 26, line 7. Basis for claim 83 is found on page 32, line 29 to page 33, line 7. Basis for claims 84 to 88 is found, for example, on pages 33 to 41, and page 67. Basis for claim 89 is found on page 21. Therefore, no new matter has been added in claims 73 to 89, and entry of the claims is respectfully requested.